Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System (OPEN)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Cordis Corporation
Massachusetts General Hospital
Prairie Education and Research Cooperative
Information provided by (Responsible Party):
Cordis Corporation Identifier:
First received: May 16, 2011
Last updated: December 12, 2013
Last verified: December 2013

This is a clinical study of a new self-expanding stent (FlexStent®) designed specifically to cope with the extreme demands of the superficial femoral artery (SFA)/proximal popliteal artery. The arteries are often abbreviated as femoropopliteal.

The intent of this study is to demonstrate that the FlexStent® Femoropopliteal Self-Expanding Stent System is safe and effective for the treatment of patients with peripheral arterial disease. Specifically, the FlexStent® shall meet or exceed the proposed safety and efficacy performance goals established for Femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease.

Condition Intervention
Peripheral Artery Disease
Peripheral Vascular Disease
Vascular Disease
Cardiovascular Diseases
Device: FlexStent® Femoropopliteal Self Expanding Stent System

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System Study

Resource links provided by NLM:

Further study details as provided by Cordis Corporation:

Primary Outcome Measures:
  • The primary safety endpoint will be a composite of all death, TLR, or index limb amputation. [ Time Frame: 30 Days ] [ Designated as safety issue: Yes ]
    The primary safety endpoint is defined as freedom from all cause death, index limb amputation and target lesion revascularization (TLR) through 30 days. The proportion of patients remaining free from this composite endpoint will be compared to a safety performance goal for bare nitinol stents.

  • The primary efficacy endpoint will be vessel patency at 12 months, defined as freedom from greater than 50% restenosis. [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
    The primary efficacy endpoint is vessel patency at 12 months. Vessel patency is defined as freedom from a greater than 50% restenosis in the stented segment as determined by the DUS peak systolic velocity ratio (PSVR) comparing data within the treated segment to the proximal normal arterial segment.

Estimated Enrollment: 257
Study Start Date: September 2011
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
This is a prospective single-arm multi-center clinical trial designed to evaluate the safety and efficacy of the Flexible Stenting Solutions Flext Stent® Femoropopliteal stenting system in subjects with lower limb peripheral arterial desease (PAD). Subjects targeted for enrollment must have a single de-novo lesion located in the superficial femoral artery and/or proximal popliteal artery with at > 70% stenosis. Subjects must meet all enrollment criteria and provide written informed consent prior to participation in the study.
Device: FlexStent® Femoropopliteal Self Expanding Stent System
Transcatheter over guidewire placement of an intravascular stent(s)
Other Names:
  • FlexStent®
  • OPEN


Ages Eligible for Study:   35 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

All subjects must meet the following criteria:

  1. Subjects, male or female, must be between the ages of 35 to 80 years inclusive at the time of consent. A female of childbearing potential may be enrolled, provided she has a negative pregnancy test within 7 days of screening.
  2. Subjects must give written informed consent prior to participation in the study and must understand the purpose of this study and be willing to adhere to the study procedures described in this protocol.
  3. Rutherford Classification Category 2-4
  4. De novo lesion in the Femoropopliteal artery, including the entire extent of the superficial femoral artery and the proximal portion of the popliteal artery extending to the medial condyle 3 cm above the knee joint
  5. Disease segment length ≤ 145mm
  6. >70% diameter stenosis and/or occlusion based on site-determined visual angiography
  7. Patent ipsilateral iliac artery
  8. Patency of ipsilateral mid/distal popliteal artery and at least 1 tibial artery with no planned intervention
  9. Target reference vessel diameter 3.5-7.5 mm.
  10. Projected life expectancy of 12 months or greater
  11. Patient is available for follow-up for 36 months and is willing and able to comply with all follow-up requirements
  12. Patient is willing and able to provide signed informed consent

Exclusion Criteria:

Any subject meeting any of the following criteria will be excluded from the study.

  1. Target vessel previously treated with a stent
  2. Target lesion within 1.5 cm of the ostium of the SFA
  3. Rutherford Classification Category 0,1,5 or 6
  4. Inability to tolerate antithrombotic or antiplatelet therapies
  5. Pregnancy (female of child-bearing age confirmed pregnant)
  6. Other comorbidity risks which in the opinion of the investigator limit longevity or likelihood of complying with protocol follow up.
  7. Serum creatinine > 2.5 mg/dL
  8. Myocardial infarction or stroke within 30 days of treatment date
  9. Known hypercoagulable state
  10. Known bleeding diathesis
  11. Untreated angiographically-evident thrombus in target vessel
  12. Patients currently enrolled in any other clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01355406

United States, Florida
Florida Research Network Recruiting
Gainesville, Florida, United States, 32605
Contact: Kurt D. Malphurs, RN, BSN    352-333-0939   
Principal Investigator: Bret N. Wiechmann, M.D.         
Mount Sinai Miami Medical Center Recruiting
Miami Beach, Florida, United States, 33140
Contact: Nancy Cabrera, CCRP    305-674-2121      
Principal Investigator: Robert Beasley, M.D.         
United States, Iowa
Midwest Cardiovascular Research Foundation / Trinity Medical Center Recruiting
Davenport, Iowa, United States, 52803
Contact: Desyree V. Weakley, RN    563-324-4384 ext 7   
Contact: Penny L. Stokes, RN, BS    563-324-4384 ext 2   
Principal Investigator: Eric J. Dippel, M.D.         
United States, Maryland
Washington Adventist Hospital / Center for Cardiac & Vascular Research Recruiting
Takoma Park, Maryland, United States, 20912
Contact: Dawn E. Shaddinger, RN, MSN CCRC    301-891-5612      
Contact: Patricia A. Miller    301-891-5405   
Principal Investigator: Fayaz Shawl, M.D., FACP         
United States, New York
Columbia University Medical Center, Center for Interventional Vascular Therapy Recruiting
New York, New York, United States, 10032
Contact: Zumara De La Cruz    212-342-3481   
Contact: Kate Dalton    212-342-3481   
Principal Investigator: William A. Gray, M.D.         
United States, Ohio
OhioHealth Research Institute Recruiting
Columbus, Ohio, United States, 43214
Contact: Marcy Hawkins, RN, CCRC    614-566-1250      
Contact: Nancy S. Sample, RN, CCRC    614-566-1267   
Principal Investigator: Mitchell J. Silver, D.O., FACC         
United States, Pennsylvania
Spirit Physician Services / Capital Cardiovascular Associates / Holy Spirit Hospital Recruiting
Camp Hill, Pennsylvania, United States, 17011
Contact: Roxanne Yost, RN, BS    717-724-6450      
Principal Investigator: Rajesh M. Dave, M.D., FACC         
United States, Washington
Providence Sacred Heart Medical Center / Providence Spokane Cardiology Recruiting
Spokane, Washington, United States, 99204
Contact: Jill Ciccarello    509-455-8820   
Principal Investigator: Pierre Leimgruber, M.D.         
United States, Wisconsin
Aurora St. Luke's Medical Center / Aurora Medical Group Recruiting
Milwaukee, Wisconsin, United States, 53215
Contact: Valerie J. Zindars, RN    414-649-6853      
Contact: Christina M. Schreiter, BSN    414-385-2472      
Principal Investigator: Mark W. Mewissen, M.D.         
Imelda Hospital / Flanders Medical Research Program Recruiting
Bonheiden, Belgium, 2820
Contact: Wendy Janssens    +32 15 50 61 82   
Principal Investigator: Patrick Peeters, MAJJ         
A.Z. Sint-Blasius Hospital / Flanders Medical Research Program Recruiting
Dendermonde, Belgium, 9220
Contact: Erwin Vinck    +32 52 25 27 35   
Principal Investigator: Marc Bosiers, M.D.         
Sponsors and Collaborators
Cordis Corporation
Massachusetts General Hospital
Prairie Education and Research Cooperative
Principal Investigator: William A. Gray, MD Center for Interventional Vascular Therapy / Columbia University Medical Center
  More Information

Responsible Party: Cordis Corporation Identifier: NCT01355406     History of Changes
Other Study ID Numbers: FSS-0003
Study First Received: May 16, 2011
Last Updated: December 12, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Cordis Corporation:
Superficial Femoral Artery or SFA
Self Expanding Stent
Bare Metal Stent

Additional relevant MeSH terms:
Cardiovascular Diseases
Peripheral Arterial Disease
Peripheral Vascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Atherosclerosis processed this record on November 27, 2014